Showing 61 - 80 results of 391 for search '(( significant decrease decrease ) OR ( significant ((we decrease) OR (small decrease)) ))~', query time: 0.48s Refine Results
  1. 61

    Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer by Kaizhao Hu (15670612)

    Published 2024
    “…Pharmacological inhibition of Skp2 has exhibited promising antitumor activity. Herein, we present the design and optimization of a series of [1,2,4]triazolo[1,5-<i>a</i>]pyrimidine-based small molecules targeting Skp2. …”
  2. 62

    Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer by Kaizhao Hu (15670612)

    Published 2024
    “…Pharmacological inhibition of Skp2 has exhibited promising antitumor activity. Herein, we present the design and optimization of a series of [1,2,4]triazolo[1,5-<i>a</i>]pyrimidine-based small molecules targeting Skp2. …”
  3. 63

    Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer by Kaizhao Hu (15670612)

    Published 2024
    “…Pharmacological inhibition of Skp2 has exhibited promising antitumor activity. Herein, we present the design and optimization of a series of [1,2,4]triazolo[1,5-<i>a</i>]pyrimidine-based small molecules targeting Skp2. …”
  4. 64

    Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer by Kaizhao Hu (15670612)

    Published 2024
    “…Pharmacological inhibition of Skp2 has exhibited promising antitumor activity. Herein, we present the design and optimization of a series of [1,2,4]triazolo[1,5-<i>a</i>]pyrimidine-based small molecules targeting Skp2. …”
  5. 65

    Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer by Kaizhao Hu (15670612)

    Published 2024
    “…Pharmacological inhibition of Skp2 has exhibited promising antitumor activity. Herein, we present the design and optimization of a series of [1,2,4]triazolo[1,5-<i>a</i>]pyrimidine-based small molecules targeting Skp2. …”
  6. 66

    MXene-Coated Liquid Metal Nanodroplet Aggregates by Mason Zadan (8667870)

    Published 2025
    “…These composites are limited by their need for high volume fractions of LM (>60 vol %) to achieve high thermal properties, introducing LM leaking as a drawback for thermal management and wearable electronic applications. In this work, we show that coating nanoscale droplets of eutectic gallium–indium (EGaIn) LM with small volume fractions of Ti<sub>3</sub>C<sub>2</sub>T<sub><i>x</i></sub> MXenes (0.25 vol %) results in a unique LM morphology in which droplets self-assemble to form semisolid aggregates. …”
  7. 67

    MXene-Coated Liquid Metal Nanodroplet Aggregates by Mason Zadan (8667870)

    Published 2025
    “…These composites are limited by their need for high volume fractions of LM (>60 vol %) to achieve high thermal properties, introducing LM leaking as a drawback for thermal management and wearable electronic applications. In this work, we show that coating nanoscale droplets of eutectic gallium–indium (EGaIn) LM with small volume fractions of Ti<sub>3</sub>C<sub>2</sub>T<sub><i>x</i></sub> MXenes (0.25 vol %) results in a unique LM morphology in which droplets self-assemble to form semisolid aggregates. …”
  8. 68

    MXene-Coated Liquid Metal Nanodroplet Aggregates by Mason Zadan (8667870)

    Published 2025
    “…These composites are limited by their need for high volume fractions of LM (>60 vol %) to achieve high thermal properties, introducing LM leaking as a drawback for thermal management and wearable electronic applications. In this work, we show that coating nanoscale droplets of eutectic gallium–indium (EGaIn) LM with small volume fractions of Ti<sub>3</sub>C<sub>2</sub>T<sub><i>x</i></sub> MXenes (0.25 vol %) results in a unique LM morphology in which droplets self-assemble to form semisolid aggregates. …”
  9. 69

    Predicting Dinitrogen Activation and Coupling with Carbon Dioxide and Other Small Molecules by Methyleneborane: A Combined DFT and Machine Learning Study by Feiying You (22119041)

    Published 2025
    “…The capture of carbon dioxide is extremely important due to the increasingly severe greenhouse effect, and the conversion of dinitrogen into high-value N–C compounds is of great significance. Here, we predict through density functional theory calculations that the coupling of dinitrogen with carbon dioxide by methyleneborane becomes favorable both thermodynamically and kinetically. …”
  10. 70
  11. 71

    Long-term divergence of nitrogen and phosphorus dynamics in small lakes across China by Shaojuan Du (22465949)

    Published 2025
    “…We showed that 33.7% of those lakes showed significant decline trend, with national TN/TP ratio of 18.7±4.2 and average decline trend of 0.99/decade (p < 0.05). …”
  12. 72

    Supplementary Material for: Supportive care for common conditions in small vulnerable newborns and term infants: the evidence by Jiang L. (4145290)

    Published 2025
    “…Introduction Small vulnerable newborns (SVN) are at an increased risk of early death and other morbidities. …”
  13. 73

    Table 4_Scalability of spheroid-derived small extracellular vesicles production in stirred systems.xlsx by Thibaud Dauphin (21196820)

    Published 2025
    “…Introduction<p>Small extracellular vesicle (sEV)-based therapies have gained widespread interest, but challenges persist to ensure standardization and high-scale production. …”
  14. 74

    Table 2_Scalability of spheroid-derived small extracellular vesicles production in stirred systems.xlsx by Thibaud Dauphin (21196820)

    Published 2025
    “…Introduction<p>Small extracellular vesicle (sEV)-based therapies have gained widespread interest, but challenges persist to ensure standardization and high-scale production. …”
  15. 75

    Table 1_Scalability of spheroid-derived small extracellular vesicles production in stirred systems.docx by Thibaud Dauphin (21196820)

    Published 2025
    “…Introduction<p>Small extracellular vesicle (sEV)-based therapies have gained widespread interest, but challenges persist to ensure standardization and high-scale production. …”
  16. 76

    Table 3_Scalability of spheroid-derived small extracellular vesicles production in stirred systems.xlsx by Thibaud Dauphin (21196820)

    Published 2025
    “…Introduction<p>Small extracellular vesicle (sEV)-based therapies have gained widespread interest, but challenges persist to ensure standardization and high-scale production. …”
  17. 77

    Image 3_Scalability of spheroid-derived small extracellular vesicles production in stirred systems.tif by Thibaud Dauphin (21196820)

    Published 2025
    “…Introduction<p>Small extracellular vesicle (sEV)-based therapies have gained widespread interest, but challenges persist to ensure standardization and high-scale production. …”
  18. 78

    Image 1_Scalability of spheroid-derived small extracellular vesicles production in stirred systems.tif by Thibaud Dauphin (21196820)

    Published 2025
    “…Introduction<p>Small extracellular vesicle (sEV)-based therapies have gained widespread interest, but challenges persist to ensure standardization and high-scale production. …”
  19. 79

    Image 2_Scalability of spheroid-derived small extracellular vesicles production in stirred systems.tif by Thibaud Dauphin (21196820)

    Published 2025
    “…Introduction<p>Small extracellular vesicle (sEV)-based therapies have gained widespread interest, but challenges persist to ensure standardization and high-scale production. …”
  20. 80

    Table 1_Repurposing of the small-molecule adrenoreceptor-inhibitor carvedilol for treatment of the fibrotic lung.xlsx by Maria Jordan (10265489)

    Published 2025
    “…</p>Methods<p>In silico modeling of dysregulated pathways in IPF and screening for putative interfering small molecules identified carvedilol as a promising anti-fibrotic agent. …”